ALNYLAM PHARMACEUTICALS, INC. Revenues
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Revenues of $1.04 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2023-02-23
- ALNYLAM PHARMACEUTICALS, INC. revenues for the quarter ending 2022-12-31 was $335.04M, a 29.59% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenues for the quarter ending 2022-09-30 was $264.31M, a 40.86% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenues for the quarter ending 2022-06-30 was $224.82M, a 1.93% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenues for the quarter ending 2022-03-31 was $213.26M, a 20.10% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenues for fiscal 2022 was $1.04B, a 22.88% increase from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. revenues for fiscal 2021 was $844.29M, a 71.31% increase from fiscal 2020.
- ALNYLAM PHARMACEUTICALS, INC. revenues for fiscal 2020 was $492.85M, a 124.28% increase from fiscal 2019.
- ALNYLAM PHARMACEUTICALS, INC. revenues for fiscal 2019 was $219.75M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2022-12-31 | $335.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $599.34M derived: sum of 2 quarters · filed 2023-02-23 | $824.16M derived: sum of 3 quarters · filed 2023-02-23 | $1.04B 10-K · filed 2023-02-23 |
| 2022-09-30 | $264.31M 10-Q · filed 2022-10-27 | $489.12M derived: sum of 2 quarters · filed 2022-10-27 | $702.38M 10-Q · filed 2022-10-27 | $960.92M derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-06-30 | $224.82M 10-Q · filed 2022-07-28 | $438.08M 10-Q · filed 2022-07-28 | $696.61M derived: sum of 3 quarters · filed 2023-02-23 | $884.25M derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-03-31 | $213.26M 10-Q · filed 2022-04-28 | $471.79M derived: sum of 2 quarters · filed 2023-02-23 | $659.43M derived: sum of 3 quarters · filed 2023-02-23 | $879.98M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-12-31 | $258.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $446.17M derived: sum of 2 quarters · filed 2023-02-23 | $666.72M derived: sum of 3 quarters · filed 2023-02-23 | $844.29M 10-K · filed 2023-02-23 |
| 2021-09-30 | $187.63M 10-Q · filed 2022-10-27 | $408.19M derived: sum of 2 quarters · filed 2022-10-27 | $585.75M 10-Q · filed 2022-10-27 | $749.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $220.55M 10-Q · filed 2022-07-28 | $398.12M 10-Q · filed 2022-07-28 | $561.68M derived: sum of 3 quarters · filed 2023-02-23 | $687.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $177.57M 10-Q · filed 2022-04-28 | $341.13M derived: sum of 2 quarters · filed 2023-02-23 | $466.98M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2020-12-31 | $163.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $289.42M derived: sum of 2 quarters · filed 2023-02-23 | $492.85M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $125.85M 10-Q · filed 2021-10-28 | $329.29M 10-Q · filed 2021-10-28 | ||
| 2019-12-31 | $219.75M 10-K · filed 2022-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |